What is the recommended anticoagulation and antiplatelet regimen after transcatheter aortic valve implantation (TAVI)?

Anticoagulation/Antiplatelet Strategy After TAVI

For patients without an indication for oral anticoagulation, aspirin 75-100 mg daily alone (single antiplatelet therapy) is the recommended strategy after TAVI, as it significantly reduces bleeding risk by more than half compared to dual antiplatelet therapy without increasing ischemic events. 1

Primary Recommendation Framework

Patients WITHOUT Indication for Oral Anticoagulation

Lifelong single antiplatelet therapy (SAPT):

• Aspirin 75-100 mg daily is reasonable (Class 2a, Level B-R) 1
• This is the preferred strategy based on the most recent evidence showing SAPT reduces major bleeding by 55-80% compared to DAPT without increasing death, stroke, or myocardial infarction 2, 3, 4

Alternative regimens (lower preference):

• Dual antiplatelet therapy (aspirin 75-100 mg + clopidogrel 75 mg) for 3-6 months may be reasonable in patients at low bleeding risk (Class 2b, Level B-NR) 1
• VKA anticoagulation (INR goal 2.5) for at least 3 months may be reasonable in patients at low bleeding risk (Class 2b, Level B-NR) 1

Patients WITH Indication for Oral Anticoagulation

Oral anticoagulation alone is recommended (Class I, Level B):

• Use VKA or appropriate DOAC for the underlying indication (e.g., atrial fibrillation) 5
• Do NOT add antiplatelet therapy routinely - OAC alone reduces bleeding by 51% compared to OAC + SAPT without increasing stroke risk 4

Critical Contraindications

DO NOT use the following after TAVI (Class 3: Harm):

• Low-dose rivaroxaban (10 mg) + aspirin is contraindicated in patients without other indications for anticoagulation (Class 3, Level B-R) 1
• This combination increased all-cause death by 78% compared to DAPT in the most recent network meta-analysis 2

Evidence Hierarchy and Reasoning

The 2021 ACC/AHA guidelines provide Class 2a recommendations for SAPT after TAVI, which represents the highest level of recommendation for this indication 1. The 2023 ESC/EACTS guidelines similarly support SAPT as the preferred strategy 5.

Why SAPT is superior:

• The 2024 network meta-analysis of 11 RCTs (n=6,415) demonstrated SAPT ranked best for both all-cause death and major bleeding 2
• The 2023 systematic review showed SAPT reduced life-threatening/major bleeding by 55% compared to DAPT (RR 0.45) without increasing ischemic events 3
• Multiple meta-analyses consistently show DAPT increases bleeding without reducing stroke, MI, or cardiovascular mortality 4, 6

Why avoid DAPT:

• Originally adopted from PCI protocols without TAVI-specific evidence 1
• The ARTE trial suggested DAPT increased major bleeding without reducing ischemic events 1
• Real-world practice has shifted away from routine DAPT, with only 82% of centers using it and median duration of just 3 months 6

Common Pitfalls to Avoid

1. Don't reflexively use DAPT - This was based on early PCI-derived protocols, not TAVI-specific evidence
2. Don't add antiplatelet therapy to OAC - Patients with atrial fibrillation or other OAC indications should receive OAC alone unless there's a separate compelling indication (e.g., recent ACS/PCI)
3. Don't use rivaroxaban-based regimens - These are explicitly contraindicated and increase mortality
4. Don't use DOACs for mechanical valves - While TAVI uses bioprosthetic valves, this remains important context

Algorithm for Decision-Making

Step 1: Does the patient have an indication for long-term oral anticoagulation (atrial fibrillation, venous thromboembolism, etc.)?

• YES → OAC alone (VKA or appropriate DOAC)
• NO → Proceed to Step 2

Step 2: Assess bleeding risk

• Low bleeding risk → Aspirin 75-100 mg daily (preferred)
• Very low bleeding risk AND strong preference for more intensive therapy → Consider DAPT for 3-6 months, then aspirin alone

Step 3: Continue aspirin 75-100 mg daily lifelong in absence of contraindications

This approach prioritizes mortality and quality of life by minimizing bleeding complications while maintaining protection against thrombotic events.